
LEXAPRO Drug Profile, 2019 - Patents, Clinical Trials, Drug Prices, Annual Sales Revenues and Raw API Sources - ResearchAndMarkets.com
The "LEXAPRO Drug Profile, 2019" report has been added to ResearchAndMarkets.com's offering.
LEXAPRO Drug Profile, 2019 is part of a deep library of business intelligence on biopharmaceutical drugs. The report focuses on LEXAPRO and covers the following critical aspects of this drug:
- United States patents
- Expired United States patents
- FDA Paragraph IV patent challenges
- District Court patent litigation
- European supplementary protection certificates (SPCs)
- Clinical trials
- Drug prices
- Annual sales revenues
- Finished product suppliers
- Raw active pharmaceutical ingredient (API) sources
Topics Covered
- Profile for LEXAPRO
- US Patents
- Expired US Patents
- Paragraph IV Patent Challenges
- US District Court Litigation
- International (ex US) Patents
- Supplementary Protection Certificates
- Clinical Trials
- Drug Prices - Average Pharmacy Cost
- Drug Prices - Best Wholesale Price
- Annual Sales Revenues
- Finished Product Suppliers
- Bulk API Sources
Companies Featured
- Allergan Inc.
- Mylan Institutional Inc.
- Blenheim Pharmacal Inc.
- Bryant Ranch Prepack
- Novoseek
- Molport
- Abi Chem
- Chemmol
- Chembase.Cn
- Acesobio
- Ak Scientific Inc. (Aksci)
- Tractus
- Abachemscene
- Medchemexpress Mce
- Wolves R&D Chemical
- A&J Pharmtech Co. Ltd.
- An Pharmatech
- Syntree
- Tocris Bioscience
- Oxchem Corporation
- Targetmol
- Boc Sciences
- Phion Ltd
- Apexbio Technology
- Labseeker
- Yuhao Chemical
- LGC Standards
- Dc Chemicals
- Ochem
- Labnetwork
- Ambinter
- Bld Pharm
- Biochempartner
- Hairui Chemical
-
and many more...
For more information about this report visit https://www.researchandmarkets.com/research/h3vfcv/lexapro_drug?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190114005407/en/
Editor Details
-
Company:
- Business Wire
- Website: